AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, long-term extension study in male and female patients with
mild to moderate Alzheimer's Disease (AD) who must have completed one of the following
studies: AAB-001-201 or AAB-001-102. All patients enrolled in Study AAB-001-251 will receive
infusions of AAB-001 (bapineuzumab), including patients randomized to placebo in Study 201
and 102. Approximately 30 study sites in the US will be involved. Each patient's
participation may vary from 3 months up to 84 months depending on the date of enrollment in
this study.
AAB-001 (bapineuzumab) is a humanized monoclonal antibody, which binds to and potentially
clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly
to the patient.
Phase:
Phase 2
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC